Clinical trial
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural…
NCT00374699 · Samsung Medical Center, Other · Completed
Key facts
| NCT number | NCT00374699 |
|---|---|
| Title | Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas |
| Official title | A Phase I/II Study of Bortezomib + CHOP in Patients With Advanced Stage Aggressive T Cell or NK/T Cell Lymphomas |
| Lead sponsor | Samsung Medical Center, Other |
| Collaborators | Janssen Medical Affairs Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-Cell Lymphomas, Non-Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | Velcade |
| Enrollment | 55 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Sep 11, 2006 |
| Last update posted | Oct 14, 2009 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: